Vor Biopharma VOR Issuance Of Pre Funded Warrants In Connection With Acquisition Of In Process Research And Development

Issuance Of Pre Funded Warrants In Connection With Acquisition Of In Process Research And Development at other companies

Corvus PharmaceuticalsCRVS

$1.26M—

ADMA BiologicsADMA

$1.4M—

Disc MedicineIRON

$0-100%

Evommune EVMN

$150—

Applied DigitalAPLD

$121.2M+232%

Navan, Inc. NAVN

$0-100%

Other financials

Income statement

See full

Operating income-$35.2M-5.6%

Net income-$219.6M-576%

EPS (diluted)-$5.11+1.9%

Balance sheet

See full

Cash & equivalents$169.9M+239%

Total debt$2.9M-90.5%

Total equity-$150.4M-328%

Total assets$506.7M+364%

Cash flow

See full

Operating cash flow-$38.2M-23.1%

CapEx$48.0K-79.2%

Free cash flow-$38.3M-22.4%

Valuation

See full

Market cap$784.61M+2,594%

Enterprise value$617.68M+5,866%

Returns & leverage

See full

Return on equity-125.4%+671pp

Debt / equity0.5×+0.2×

Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept vor:IssuanceOfPreFundedWarrantsInConnectionWithAcquisitionOfInProcessResearchAndDevelopment.

The official record: Vor Biopharma’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's issuance of pre funded warrants in connection with acquisition of in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vor Biopharma's issuance of pre funded warrants in connection with acquisition of in process research and development?: Vor Biopharma (VOR) reported issuance of pre funded warrants in connection with acquisition of in process research and development of $44.34M in Q4 2025.
What does issuance of pre funded warrants in connection with acquisition of in process research and development mean?: This represents the non-cash consideration provided in the form of pre-funded warrants to acquire intellectual property or research and development assets. It highlights the company's strategy for inorganic growth and pipeline expansion.